Exousia Bio, Inc. 10-Q — AI Bull & Bear Analysis

The latest 10-Q filing for Exousia Bio reveals a company in the midst of a high-stakes identity shift. By shedding its legacy education business and acquiring Exousia AI, the firm has traded a dormant shell status for a high-risk, high-reward biotech play. However, the transition is marred by a total absence of cash and a reliance on related-party financing to sustain basic operations. Investors are now faced with a stark trade-off: the potential of a breakthrough in exosome therapeutics versus the immediate reality of a company on the brink of insolvency. The recent rescission of a 21-million-share issuance to Progenicyte Japan further highlights the volatility of the company's capital structure as it attempts to stabilize its governance and funding requirements.